DK2513105T3 - 2-arylimidazolderivater som pde10a-enzyminhibitorer - Google Patents

2-arylimidazolderivater som pde10a-enzyminhibitorer

Info

Publication number
DK2513105T3
DK2513105T3 DK10797990.8T DK10797990T DK2513105T3 DK 2513105 T3 DK2513105 T3 DK 2513105T3 DK 10797990 T DK10797990 T DK 10797990T DK 2513105 T3 DK2513105 T3 DK 2513105T3
Authority
DK
Denmark
Prior art keywords
enzymin
arylimidazold
pde10a
inhibitors
derivatives
Prior art date
Application number
DK10797990.8T
Other languages
English (en)
Inventor
Ask Püschl
Mauro Marigo
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Rd Morten Langg
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK2513105T3 publication Critical patent/DK2513105T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK10797990.8T 2009-12-17 2010-12-15 2-arylimidazolderivater som pde10a-enzyminhibitorer DK2513105T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28732409P 2009-12-17 2009-12-17
DKPA200901341 2009-12-17
PCT/DK2010/050343 WO2011072696A1 (en) 2009-12-17 2010-12-15 2-arylimidazole derivatives as pde10a enzyme inhibitors

Publications (1)

Publication Number Publication Date
DK2513105T3 true DK2513105T3 (da) 2014-07-14

Family

ID=44246810

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10797990.8T DK2513105T3 (da) 2009-12-17 2010-12-15 2-arylimidazolderivater som pde10a-enzyminhibitorer

Country Status (34)

Country Link
US (2) US8501797B2 (da)
EP (1) EP2513105B1 (da)
JP (1) JP5698761B2 (da)
KR (1) KR101777889B1 (da)
CN (1) CN102753551B (da)
AR (1) AR079498A1 (da)
AU (1) AU2010333437B2 (da)
CA (1) CA2783727C (da)
CO (1) CO6612246A2 (da)
CR (1) CR20120317A (da)
CY (1) CY1115278T1 (da)
DK (1) DK2513105T3 (da)
DO (1) DOP2012000168A (da)
EA (1) EA021415B1 (da)
ES (1) ES2484692T3 (da)
GE (1) GEP20156242B (da)
GT (1) GT201200180A (da)
HK (1) HK1177739A1 (da)
HR (1) HRP20140632T1 (da)
MA (1) MA33924B1 (da)
MX (1) MX2012007144A (da)
MY (1) MY158202A (da)
NZ (1) NZ600416A (da)
PL (1) PL2513105T3 (da)
PT (1) PT2513105E (da)
RS (1) RS53413B (da)
SG (1) SG181536A1 (da)
SI (1) SI2513105T1 (da)
SM (1) SMT201400114B (da)
TN (1) TN2012000287A1 (da)
TW (1) TWI481607B (da)
UA (1) UA107817C2 (da)
WO (1) WO2011072696A1 (da)
ZA (1) ZA201204418B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
EP3453708B8 (en) 2010-12-17 2022-03-16 Novartis AG Process for the preparation of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine di-hydrochloride
RS56795B1 (sr) 2010-12-17 2018-04-30 Reata Pharmaceuticals Inc Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
CA2824047C (en) 2011-01-11 2019-06-18 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
EP2748151B1 (en) * 2011-08-25 2016-03-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
TWI764950B (zh) * 2016-11-02 2022-05-21 比利時商健生藥品公司 Ｐｄｅ２抑制劑
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
PL375256A1 (en) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2006509832A (ja) 2002-10-30 2006-03-23 ニューロ３デー サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用
JP2009513494A (ja) 2003-06-30 2009-04-02 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ１０阻害剤としてのピロロジヒドロイソキノリン
ATE438398T1 (de) 2003-06-30 2009-08-15 Nycomed Gmbh Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
WO2005082883A2 (en) 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
WO2005120514A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
WO2006028957A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
US20090176829A1 (en) * 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
ES2392553T3 (es) * 2006-07-10 2012-12-11 H. Lundbeck A/S Derivados (3-aril-piperazina-1-ilo) de 6,7-dialcoxiquinazolina, 6,7-dialcoxiftalazina y 6,7-dialcoxiisoquinolina
JP2010533715A (ja) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系ｐｋｂ調節剤
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物

Also Published As

Publication number Publication date
WO2011072696A1 (en) 2011-06-23
SMT201400114B (it) 2014-11-10
SG181536A1 (en) 2012-07-30
SI2513105T1 (sl) 2014-11-28
HRP20140632T1 (hr) 2014-09-26
JP2013514285A (ja) 2013-04-25
GT201200180A (es) 2015-01-16
US20130289038A1 (en) 2013-10-31
CA2783727C (en) 2018-02-20
HK1177739A1 (en) 2013-08-30
EP2513105A1 (en) 2012-10-24
PL2513105T3 (pl) 2014-09-30
MX2012007144A (es) 2012-07-03
KR20120123276A (ko) 2012-11-08
UA107817C2 (en) 2015-02-25
EP2513105B1 (en) 2014-05-14
CO6612246A2 (es) 2013-02-01
TN2012000287A1 (en) 2013-12-12
DOP2012000168A (es) 2012-11-30
ZA201204418B (en) 2013-08-28
CY1115278T1 (el) 2017-01-04
CN102753551B (zh) 2014-10-22
PT2513105E (pt) 2014-07-31
KR101777889B1 (ko) 2017-09-12
GEP20156242B (en) 2015-02-10
TWI481607B (zh) 2015-04-21
CA2783727A1 (en) 2011-06-23
US20120302548A1 (en) 2012-11-29
NZ600416A (en) 2013-08-30
MA33924B1 (fr) 2013-01-02
US8927738B2 (en) 2015-01-06
AU2010333437B2 (en) 2016-09-01
JP5698761B2 (ja) 2015-04-08
AR079498A1 (es) 2012-02-01
EA201290518A1 (ru) 2013-01-30
TW201127831A (en) 2011-08-16
CR20120317A (es) 2012-08-16
US8501797B2 (en) 2013-08-06
AU2010333437A1 (en) 2012-06-21
CN102753551A (zh) 2012-10-24
MY158202A (en) 2016-09-15
ES2484692T3 (es) 2014-08-12
RS53413B (en) 2014-12-31
EA021415B1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
CY2020023I2 (el) Αναστολεiς βητα-λακταμασων
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK2406253T3 (da) Benzofuranylderivater anvendt som glucokinase-inhibitorer
DK2899191T3 (da) Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
DK2448938T3 (da) Pyrimidinoner som pi3k-inhibitorer
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer
SMT201500271B (it) Inibitori di neprilisina
DK2414362T3 (da) Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
BR112012000525A2 (pt) inibidores da bace
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK2389382T3 (da) Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
DK3354652T3 (da) Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2162131T3 (da) Quinolin-derivativer som pi3-kinase-inhibitorer
DK2470546T3 (da) HEXAHYDROOXAZINOPTERIDIN- forbindelser til anvendelse som mTOR INHIBITORER
DK3196202T3 (da) Heterocyclylaminer som pi3k-inhibitorer
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
ECSP12011999A (es) Derivados benzamida sustituidos
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
DK2397480T3 (da) Diazepindionderivat
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
BRPI0918564A2 (pt) inibidores
DK2513107T3 (da) Heteroaromatiske phenylimidazol-derivater som pde10a-enzyminhibitorer
DK2275414T3 (da) Cyclopentylacrylamidderivat